SCHEMBL3016337

SCHEMBL3016337

Cc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(C)c(Cl)cc4Cl)CC3)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
LMNA P02545 1/20 0.34
DNM1L O00429 7/20 0.34
CHRM5 P08912 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
GBA1 P04062 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003075 0.94 MAPT (0.36) SMN1; SMN2LMNACHRM5MAPTKMT2A
SCHEMBL3015249 0.94 CNR1 (0.35) SMN1; SMN2LMNADNM1LCHRM5KMT2A
SCHEMBL3012261 0.93 LMNA (0.40) LMNADNM1LCHRM5ALDH1A1MAPT
SCHEMBL3008578 0.92 LMNA (0.33) LMNADNM1LCHRM5KMT2ACNR1
SCHEMBL3001757 0.92 CNR1 (0.35) LMNADNM1LCHRM5KMT2ACNR1
SCHEMBL3010481 0.92 LMNA (0.38) LMNADNM1LCHRM5MAPTCNR1
SCHEMBL3015088 0.92 CHRM5 (0.35) LMNADNM1LCHRM5CNR1CNR2
SCHEMBL3020081 0.91 RAB9A (0.38) SMN1; SMN2NPC1RAB9AALDH1A1POLB
SCHEMBL3007705 0.91 CHRM5 (0.35) SMN1; SMN2RAB9ALMNADNM1LCHRM5
SCHEMBL3003947 0.90 CACNA1G (0.37) SMN1; SMN2NPC1RAB9ALMNADNM1L

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885NPC1 15/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.